TAC T-cells for the Treatment of HER2-positive Solid Tumours

Official Title

A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumours


TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor. This is an open-label, multicentre Phase 1/2 study that aims to establish safety, Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 in subjects with relapsed or refractory solid tumours.

Trial Description

Primary Outcome:

  • Incidence of Treatment-Emergent Adverse Events
Secondary Outcome:
  • Determine MTD or RP2D
  • Determine expansion of TAC01-HER2
  • Determine persistence of TAC01-HER2
  • Evaluate Overall Response Rate (ORR)
  • Evaluate Overall Survival (OS)
Phase I: Dose escalation in any 3+ HER2-positive solid tumour. Phase II: Dose expansion cohorts: 3+ HER2-positive breast cancer (a) and other solid tumours (b) 2+HER2-positive solid tumours (c).

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society